Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients
A brief review of the key efficacy data for two treatment options, Ibrutinib and Belumosudil, in patients with chronic GvHD.
EP: 1.The Chronic GvHD Landscape: Risk Factors and Diagnosis
EP: 2.First-line Treatment for Patients with Chronic GvHD
EP: 3.Defining and Managing Steroid Refractory Chronic GvHD
EP: 4.Role of Ruxolitinib in Steroid-Refractory Chronic GvHD
EP: 5.Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil
Now Viewing
EP: 6.Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients
EP: 7.Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD
EP: 8.Future Directions in Chronic GvHD
Related Videos
Related Content
